INC Research Holdings Inc (INCR) was Downgraded by Robert W. Baird to ” Neutral” while Lowering the Price Target of the company shares to $ 51 from a previous price target of $55 . Earlier the firm had a rating of “Outperform ” on the company shares. Robert W. Baird advised their investors in a research report released on May 3, 2016.
Many Wall Street Analysts have commented on INC Research Holdings Inc. JP Morgan Initiated INC Research Holdings Inc on Mar 24, 2016 to “Overweight”, Price Target of the shares are set at $47.
On the company’s financial health, INC Research Holdings Inc reported $0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 2, 2016. Analyst had a consensus of $0.54. The company had revenue of $249.00 million for the quarter, compared to analysts expectations of $238.28 million. The company’s revenue was up 17.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.42 EPS.
INC Research Holdings Inc closed down -0.68 points or -1.41% at $47.45 with 17,39,776 shares getting traded on Monday. Post opening the session at $48.99, the shares hit an intraday low of $45.52 and an intraday high of $48.99 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Apr 19, 2016, James T. Ogle (director) sold 114,806 shares at $50.00 per share price. According to the SEC, on Apr 14, 2016, D. Jamie Macdonald (Chief Executive Officer) sold 94,675 shares at $48.00 per share price. On Apr 4, 2016, Michael Gibertini (President Clinical Development) sold 9,000 shares at $40.78 per share price, according to the Form-4 filing with the securities and exchange commission.
INC Research Holdings Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company’s segment Clinical Development Services offers a variety of clinical development services including global studies clinical monitoring investigator recruitment patient recruitment data management and study reports. The Company’s segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Company’s segment Global Consulting provides consulting services regarding clinical trial regulatory affairs regulatory consulting services quality assurance audits and pharmacovigilance consulting non-clinical consulting and medical writing consulting.